The German pharmaceutical drug researcher Evotec has to look for a new boss. The CEO Werner Lanthaler, who comes from Eggelsberg in the Braunau district, is resigning following almost 15 years for personal reasons before his contract expires, the MDax-listed company surprisingly announced on Wednesday evening in Hamburg. The supervisory board has agreed to the resignation and is looking for a permanent successor within and outside of the company.
For the time being, supervisory board member Mario Polywka is expected to manage the company. This one had Evotec used to run the day-to-day business.
Lanthaler justified his resignation with an “extremely challenging and both physically and overall exhausting year 2023”. He “cannot serve the company in the best possible way” in the next few years. Supervisory Board Chairman Iris Löw-Friedrich thanked the manager “for his unique vision and the many important successes over the past almost 15 years.” Lanthaler’s contract would actually have run until March 2026.
